Immunogenic Effects
Immunogenic Effects - Related Videos
05:42
Using a Sandwich ELISA to Determine the Immunogenic Glycoprotein Content in a Vaccine
0 Views •
2025
This video showcases an indirect enzyme-linked immunosorbent assay or ELISA sandwich immunocapture assay designed to assess immunogenic glycoprotein levels in vaccines. The assay plate, containing glycoprotein-specific antibodies, is incubated with serially diluted vaccine samples, including reference and test vaccines, followed by immunoassay to quantify glycoprotein content in the test vaccine.
10:52
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
0 Views •
Cited by 10 •
2010
Autoimmune hypophysitis can be reproduced in mice by injecting an extract of mouse pituitary proteins.
12:08
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
0 Views •
Cited by 10 •
2019
The transimmunization (TI) device or plate and related protocols have been developed to replicate the key features of extracorporeal photochemotherapy (ECP), in an experimental setting, allowing for production of physiologically activated, tunable dendritic cells (DCs) for cancer immunotherapy.
12:54
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
0 Views •
Cited by 1 •
2023
The methodology describes the generation of bovine monocyte-derived dendritic cells (MoDCs) and their application for the in vitro evaluation of antigenic candidates during the development of potential veterinary vaccines in cattle.
02:19
Buffer Effectiveness
0 Views •
2020
Buffer solutions do not have an unlimited capacity to keep the pH relatively constant . Instead, the ability of a buffer solution to resist changes in pH relies on the presence of appreciable amounts of its conjugate weak acid-base pair. When enough strong acid or base is added to substantially lower the concentration of either member of the buffer pair, the buffering action within the solution is compromised. The buffer capacity is the amount of acid or base that can be added to a given volume...
FAQs
Immune recognition starts when immune cells detect molecular patterns associated with an antigen, therapeutic substance, biomaterial, or other foreign signal. This recognition determines whether the signal enters pathways involving antigen processing and presentation. The resulting cellular response can influence whether exposure leads toward protective immunity, inflammation, or another unwanted immune reaction.
Antigen processing breaks down recognized material so that relevant antigenic information can be presented to immune cells. This presentation helps activate T lymphocytes, which coordinate downstream immune activity and support B-lymphocyte responses. Because this step connects recognition with adaptive activation, it strongly shapes antibody production, cytokine release, and later immune memory.
These outcomes represent complementary parts of the response. Antibodies provide antigen-directed immune activity, while cytokines are released signals that influence communication and inflammation among immune cells. Immune memory preserves information about a prior encounter. Together, they can support protection, but excessive or inappropriate activity may contribute to unwanted immune effects.
The biological value of an immune response depends on its purpose and intensity. In vaccine development, activating immunity and memory can support protection. With biologic medicines or implanted materials, comparable recognition may instead produce inflammation or adverse responses. Evaluating the context helps distinguish a desired immune outcome from a potentially harmful one.
A useful evaluation follows the response from initial molecular recognition through antigen processing and presentation, T- and B-lymphocyte activation, and downstream outcomes. Researchers can then consider antibody production, cytokine release, immune memory, inflammation, or adverse responses. This sequence links cellular mechanisms to practical decisions about safety, effectiveness, and immune control.
Vaccine development uses immunogenicity evaluation to determine whether an intervention can produce the intended immune activity. Researchers focus on responses such as lymphocyte activation, antibody production, cytokine release, and immune memory because these outcomes indicate how exposure may support protection. The same assessment also helps identify immune activity that could be undesirable.
For biologic medicines, evaluation helps predict whether the treatment may trigger unwanted antibody, cytokine, or inflammatory responses. For implanted materials, assessment examines how the body responds to the foreign biomaterial and whether immune activation could create adverse effects. These evaluations inform efforts to develop safer therapies and materials while controlling inappropriate immune activity.